Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Summit Therapeutics Inc. Common Stock

SMMT

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Last trade $10.78
Day change -$1.045 (-8.84%)
Day range $10.54 – $12.05
Volume 9,831,272
Market cap $9.45B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$9.45B
Price / earnings
—
Price / book
16.74×
Price / sales
—
EV / sales
—
EV / EBITDA
-10.88×

Profitability

Earnings per share
-$1.04
Return on assets
-120.19%
Return on equity
-147.47%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
5.99×
Quick ratio
5.99×
Cash ratio
1.37×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$526.88M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SMMT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$45.48M$62.76M$62.59M$77.63M$103.12M$360.42M$15.59M$14.23M
Research and development$169.13M$157.73M$132.62M$147.29M$131.1M$208.02M$51.27M$66.39M
Total operating expenses$214.61M$220.5M$195.21M$224.93M$234.21M$568.44M$66.85M$65.61M
Operating income-$214.61M-$220.5M-$195.21M-$224.93M-$234.21M-$568.44M-$66.85M-$65.61M
Interest expense$0$0$0$0$0$0$0-$9K
Income before taxes-$208.39M-$215.67M-$189.42M-$219.17M-$231.79M-$565.9M-$62.91M-$61.2M
Income taxes$0$0$0$0$0$0$0$0
Net income-$208.39M-$215.67M-$189.42M-$219.17M-$231.79M-$565.9M-$62.91M-$61.2M
Net income attributable to common shareholders-$208.39M-$215.73M-$189.42M-$219.17M-$231.79M-$565.9M-$62.91M-$61.2M
EBITDA-$214.53M-$220.45M-$195.17M-$224.88M-$234.17M-$568.4M-$66.83M-$80.6M
Basic earnings per share-$0.26-$0.28-$0.24-$0.29-$0.31-$0.76-$0.09-$0.08
Diluted earnings per share-$0.26-$0.28-$0.24-$0.29-$0.31-$0.76-$0.09-$0.08

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Summit Stock Falls on FDA Rejection for Lung Cancer Drug

Summit Therapeutics received an FDA Complete Response Letter (CRL) for ivonescimab plus chemotherapy in NSCLC patients, declining approval due to insufficient evidence of effectiveness. While the HARMONi trial met its progression-free survival endpoint, it failed to demonstrate statistically significant overall survival benefit. The decision represents a major regulatory setback, delaying the company's first marketed product and U.S. commercial revenues.

The Motley Fool

Breakfast News: Summit’s FDA Setback Isn’t the End

Summit Therapeutics' shares plunged over 20% after receiving an FDA Complete Response Letter for its cancer drug ivonescimab, failing to meet overall survival statistical requirements in the HARMONi trial. However, analysts view the setback as limited since it affects only second-line treatment, with the drug's main blockbuster potential in first-line settings. Summit has 17 ongoing late-stage trials, strong financial backing from AstraZeneca, and $630 million in cash reserves to continue development.

Zacks Investment Research

Wall Street Analysts See a 62.33% Upside in Summit Therapeutics (SMMT): Can the Stock Really Move This High?

Summit Therapeutics (SMMT) has gained 4.1% over the past four weeks and trades at $17.84. Wall Street analysts project a mean price target of $28.96, indicating a potential 62.3% upside. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions with a 5.2% increase over the past month. However, the article cautions that price targets should not be the sole basis for investment decisions, as they often reflect analyst bias and business incentives rather than accurate predictions.

Zacks Investment Research

SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in Focus

Summit Therapeutics reported a Q3 2026 loss per share of 26 cents, beating expectations, with lower G&A expenses offsetting increased R&D spending. The company secured a $2 billion strategic equity investment from AstraZeneca post-quarter. Summit is advancing its lead candidate ivonescimab across multiple solid tumors, with FDA decision expected by November 14, 2026 for EGFR-mutant NSCLC. New collaborations with AstraZeneca and Daiichi Sankyo are expanding ivonescimab combinations into additional cancer types.

Zacks Investment Research

AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth

AstraZeneca reported Q3 2026 core earnings of $2.79 per share, beating consensus estimates of $2.60, with revenues rising 7% to $16.21 billion. Strong growth in Oncology (up 17% to $7.77 billion) led by Tagrisso, Imfinzi, and Calquence offset weakness in mature drugs facing generic competition like Farxiga and Brilinta. The company reaffirmed 2026 guidance expecting low double-digit core EPS growth and targets $80 billion in revenues by 2030 with 20 new medicine launches planned.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.